3-(4-氨基苯氧基)-吡咯烷-1-羧酸叔丁酯 | 862874-75-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(4-氨基苯氧基)-吡咯烷-1-羧酸叔丁酯
• 英文名称: 3-(4-amino-phenoxy)-pyrrolidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-Butyl 3-(4-aminophenoxy)pyrrolidine-1-carboxylate
• CAS: 862874-75-7
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.351
• InChiKey: RYWQNZFJMSYAED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

文献信息

• Inhibitors of Diacylglycerol Acyltransferase
  申请人：Bolin David Robert

  公开号：US20100152445A1

  公开（公告）日：2010-06-17

  Provided herein are amides containing at least a four ring structure, which are inhibitors of diacylglycerol acyltransferase and are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了至少含有四环结构的酰胺，这些酰胺是甘油二酰基转移酶的抑制剂，可用于治疗肥胖、2型糖尿病和代谢综合征等疾病。
• DIAMINOTHIAZOLES
  申请人：——

  公开号：US20040006058A1

  公开（公告）日：2004-01-08

  The present invention is directed to novel diaminothiazoles of formula 1 These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.

  本发明涉及一种新型的formula1的二氨基噻唑化合物。这些化合物抑制细胞周期依赖性激酶4（Cdk4），并且对Cdk2和Cdk1具有选择性。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是固体肿瘤方面具有用途。本发明还涉及含有这些化合物的药物组合物，以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺部、结肠和前列腺肿瘤的方法。
• INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Bolin David Robert

  公开号：US20100145047A1

  公开（公告）日：2010-06-10

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。
• NAMPT INHIBITORS
  申请人：AbbVie Inc.

  公开号：US20170065575A1

  公开（公告）日：2017-03-09

  Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

  揭示了抑制NAMPT活性的化合物，含有这些化合物的组合物以及治疗NAMPT表达疾病的方法。
• 4-aminopyrimidine-5-one derivatives
  申请人：——

  公开号：US20040162303A1

  公开（公告）日：2004-08-19

  Novel 4-aminopyrimidine-5-one derivatives are disclosed. These compounds inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 4-aminopyrimidine-5-one derivatives.

  本发明揭示了新型4-氨基嘧啶-5-酮衍生物。这些化合物抑制细胞周期蛋白依赖性激酶，特别是细胞周期蛋白依赖性激酶4（Cdk4）。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并可用于治疗或控制癌症，特别是实体瘤。本发明还涉及含有这些化合物的制药组合物以及治疗或控制癌症的方法，尤其是乳腺、肺、结肠和前列腺肿瘤的治疗或控制。此外，还揭示了制备这些新型4-氨基嘧啶-5-酮衍生物的中间体。